Secondary prevention of ischemic stroke: A 1998 US perspective

Cerebrovascular Diseases

Volumn 9, Issue SUPPL. 3, 1999, Pages 37-44

  Sacco, Ralph L ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; WARFARIN;

ACUTE HEART INFARCTION; ALCOHOL CONSUMPTION; BRAIN INFARCTION; CONFERENCE PAPER; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; STROKE;

EID: 0032810284     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047553     Document Type: Conference Paper

References (30)

1. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med 1991;325:445-453.
2. Mayberg MR, Wilson SE, Yatsu F et al: Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. JAMA 1991;266:3289-3294.
3. European Carotid Surgery Trialists' Collaborative Group: NRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991;337:1235-1243.
4. European Carotid Surgery Trialists' Collaborative Group: Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379-1387.
5. Barnett HJM, Taylor DW, Eliasziw M et al for the North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients: Final results. N Engl J Med 1998; 339:1415-1425.
6. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, Pessin MS, Weichel E, Sila CA, Furlan AJ, Kargman DE, Sacco RL, Wityk RJ, Ford G, Fayad PB, for the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group: The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995;45:1488-1493.
7. Albers GW: Atrial fibrillation and stroke. Three new studies, three new questions. Arch Intern Med 1994;154:1443-1448.
8. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
9. European Atrial Fibrillation Trial Study Group: Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
10. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J: A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:524-529.
11. The Stroke Prevention in Reversible Ischemia (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865.
12. The WARSS, APASS, PICSS, and HAS Study Groups: The feasibility of a collaborative double-blind study using an anticoagulant: The Warfarin-Aspirin Recurrent Stroke Study (WARSS), the Antiphospholipid Antibodies and Stroke Study (APASS), the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), and the Hemostatic System Activation Study (HAS). Cerebrovasc Dis 1997;7: 100-112.
13. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
14. The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
15. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-1266.
16. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
17. Gent M, Blakely J, Easton JD et al and the CATS Group: The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;i:1215-1220.
18. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B, for the Ticlopidine Aspirin Stroke Study Group: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
19. CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
20. Alter M, Sobel E, McCoy RL et al: Stroke in the Lehigh Valley: Risk factors for recurrent stroke. Neurology 1987;37:503-507.
21. Hornig CR, Lammers C, Buttner T, Hoffmann O, Dorndorf W: Long-term prognosis of infratentorial transient ischemic attacks and minor strokes. Stroke 1992;23:199-204.
22. Hypertension-Stroke Cooperative Study Group: Effect of antihypertensive treatment on stroke recurrence. JAMA 1974;229:409-418.
23. Beevers DG, Fairman MJ, Hamilton M et al: Antihypertensive treatment and the course of established cerebral vascular disease. Lancet 1973;i:1407.
24. Sobel E, Alter M, Davanipour Z, Friday G, McCoy R, Levitt LP, Isack T: Stroke in the Lehigh Valley: Combined risk factors for recurrent ischemic stroke. Neurology 1989;39:669-672.
25. Sacco RL, Shi T, Zamanillo MC, Kargman D: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study. Neurology 1994;44:626-634.
26. Sacco RL: Risk factors and outcomes for ischemic stroke. Neurology 1995;45(suppl 1):10-14.
27. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP: Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 1992;23:1250-1256.
28. Hier DB, Foulkes MA, Swiontoniowski M, Sacco RL, Gorelick PB, Mohr JP, Price TR, Wolf PA: Stroke recurrence within two years after ischemic infarction. Stroke 1991;22:155-161.
29. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-321.
30. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA: Risk Factors Panel - American Heart Association Prevention Conference IV. Stroke 1997;28:1507-1517.